Skip to main content

Table 1 Summary of the patient samples included in this study

From: Genetically-controlled Vesicle-Associated Membrane Protein 1 expression may contribute to Alzheimer’s pathophysiology and susceptibility

  Total CTRLs AD
Series N N %F %ε4+ Age N %F %ε4+ Age
A) Mayo postmortem 365 173 35.3 26.0 71.7 192 51.6 63.0 73.5
B) All 10,842 6,175 54.4 23.4 77.6 4,667 61.1 62.3 76.6
Mayo Clinic 6,307 4,250 54.0 23.3 78.7 2,057 60.7 59.9 79.3
NCRAD 910 209 61.7 16.3 78.3 701 64.8 78.5 75.2
Norway 927 569 59.6 24.6 74.9 358 69.8 63.1 79.4
ARUK 2,698 1,147 51.6 24.2 74.7 1,551 58.0 58.0 73.0
  1. Demographic details are shown for (A) Samples taken from the cerebellum of autopsy-confirmed AD patients and controls and used for genotype versus mRNA analyses and (B) Samples from the Mayo Clinic, Indiana, Norway and Alzheimer’s Research UK (ARUK) Consortium case-control series used for the case-control association study. N; number of samples, %F; percent females, %ε4; percent APOE ε4 carriers, Age; years.